DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
EP2265270A1
(en)
|
2008-02-04 |
2010-12-29 |
OSI Pharmaceuticals, Inc. |
2-aminopyridine kinase inhibitors
|
AR070317A1
(es)
|
2008-02-06 |
2010-03-31 |
Osi Pharm Inc |
Furo (3,2-c) piridina y tieno (3,2-c) piridinas
|
CN101998959B
(zh)
*
|
2008-02-06 |
2013-08-28 |
生物马林药物股份有限公司 |
聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
AU2009313198B2
(en)
|
2008-11-10 |
2016-03-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
TWI396689B
(zh)
|
2008-11-14 |
2013-05-21 |
Amgen Inc |
作為磷酸二酯酶10抑制劑之吡衍生物
|
WO2010065579A2
(en)
*
|
2008-12-02 |
2010-06-10 |
E. I. Du Pont De Nemours And Company |
Fungicidal heterocyclic compounds
|
RU2016141566A
(ru)
|
2008-12-19 |
2018-12-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Производные пиразина, используемые в качестве ингибиторов киназы atr
|
NZ594172A
(en)
|
2008-12-22 |
2013-04-26 |
Merck Patent Gmbh |
Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{ 3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl} -2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
|
DE102009033208A1
(de)
|
2009-07-15 |
2011-01-20 |
Merck Patent Gmbh |
Aminopyridinderivate
|
AR078984A1
(es)
*
|
2009-11-13 |
2011-12-14 |
Astrazeneca Ab |
Pirazina sustituida con oxazolo (4,5-c) piridina
|
WO2011143423A2
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
MX2012013082A
(es)
|
2010-05-12 |
2013-05-09 |
Vertex Pharma |
Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
|
WO2011143419A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Pyrazines useful as inhibitors of atr kinase
|
WO2011143425A2
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
JP2013526538A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
EP2569313A1
(en)
|
2010-05-12 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
UY33452A
(es)
|
2010-06-16 |
2012-01-31 |
Bayer Schering Pharma Ag |
Triazolopiridinas sustituidas
|
EP2585468A1
(en)
|
2010-06-23 |
2013-05-01 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
EP2588107A1
(en)
|
2010-07-01 |
2013-05-08 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
JP5970003B2
(ja)
*
|
2011-03-04 |
2016-08-17 |
ローカス ファーマシューティカルズ インコーポレイテッド |
アミノピラジン化合物
|
CN102718745A
(zh)
*
|
2011-03-30 |
2012-10-10 |
中国科学院上海药物研究所 |
新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
WO2012138809A1
(en)
*
|
2011-04-05 |
2012-10-11 |
Dawei Zhang |
Heterocyclic compounds as kinase inhibitors
|
WO2012138938A1
(en)
|
2011-04-05 |
2012-10-11 |
Vertex Pharmaceuticals Incorporated |
Aminopyrazine compounds useful as inhibitors of tra kinase
|
PL2714677T3
(pl)
|
2011-05-23 |
2019-02-28 |
Merck Patent Gmbh |
Pochodne pirydynowe i pirazynowe
|
EP2714668B9
(en)
|
2011-05-23 |
2017-06-14 |
Merck Patent GmbH |
Thiazole derivatives
|
US9096602B2
(en)
|
2011-06-22 |
2015-08-04 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
US8822469B2
(en)
|
2011-06-22 |
2014-09-02 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
|
CN103732588B
(zh)
*
|
2011-07-27 |
2016-10-12 |
南京奥昭生物科技有限公司 |
螺环分子作为蛋白激酶抑制剂
|
DE102011112978A1
(de)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
EP2751088B1
(en)
|
2011-09-30 |
2016-04-13 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP3733185B1
(en)
|
2011-09-30 |
2022-12-07 |
Vertex Pharmaceuticals Incorporated |
Treating non-small cell lung cancer with atr inhibitors
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
AU2012315611A1
(en)
|
2011-09-30 |
2014-04-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
CN106496173A
(zh)
|
2011-09-30 |
2017-03-15 |
沃泰克斯药物股份有限公司 |
用于制备可用作atr激酶抑制剂的化合物的方法
|
CN103087050A
(zh)
*
|
2011-10-28 |
2013-05-08 |
山东轩竹医药科技有限公司 |
芳基激酶抑制剂
|
EP2776422A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
WO2013071088A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2776429A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
US8841449B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
WO2013071093A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
DE102011119127A1
(de)
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
RS55728B1
(sr)
*
|
2012-01-31 |
2017-07-31 |
Daiichi Sankyo Co Ltd |
Derivat piridona
|
LT2812337T
(lt)
|
2012-02-09 |
2016-11-25 |
Merck Patent Gmbh |
Furo[3,2-b]piridino dariniai, kaip tbk1 ir ikk inhibitoriai
|
WO2013148537A1
(en)
*
|
2012-03-29 |
2013-10-03 |
Ning Xi |
Substituted spirobicyclic compounds and methods of use
|
DK2833973T3
(en)
|
2012-04-05 |
2018-01-02 |
Vertex Pharma |
Compounds useful as ATR kinase inhibitors and combination therapies thereof
|
US9096579B2
(en)
|
2012-04-20 |
2015-08-04 |
Boehringer Ingelheim International Gmbh |
Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
|
WO2013162061A1
(ja)
*
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
二環性ピリミジン化合物
|
LT3176170T
(lt)
|
2012-06-13 |
2019-04-25 |
Incyte Holdings Corporation |
Pakeisti tricikliniai junginiai, kaip fgfr inhibitoriai
|
KR101245559B1
(ko)
*
|
2012-06-29 |
2013-03-22 |
한국화학연구원 |
신규 다중치환 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
WO2014062604A1
(en)
|
2012-10-16 |
2014-04-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
ME03036B
(me)
|
2012-12-07 |
2018-10-20 |
Vertex Pharma |
2-amin0-6-fluoro-n-( 5-fluoro-4-( 4-( 4-( oksetan -3-il)piperrazin -1-karbonil)piperidin-1-il)piridin-3-il )pirazol0[1,5alfa] pirimidin-3-karboksamid kao inhibitor atr kinaze
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
TWI498325B
(zh)
|
2013-01-18 |
2015-09-01 |
Hoffmann La Roche |
3-取代吡唑及其用途
|
MA38287B1
(fr)
|
2013-01-23 |
2018-08-31 |
Astrazeneca Ab |
Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
|
KR101791762B1
(ko)
*
|
2013-02-02 |
2017-11-20 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
치환된 2-아미노피리딘 단백질 키나제 억제제
|
EP2970311A4
(en)
|
2013-03-14 |
2016-11-23 |
Brigham & Womens Hospital |
BMP HEMMER AND METHOD OF USE THEREOF
|
US9663519B2
(en)
|
2013-03-15 |
2017-05-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
AU2014253798C1
(en)
|
2013-04-19 |
2019-02-07 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
EP3071204B1
(en)
|
2013-11-20 |
2019-02-20 |
SignalChem Lifesciences Corp. |
Quinazoline derivatives as tam family kinase inhibitors
|
EP3074390B1
(en)
|
2013-11-27 |
2020-07-08 |
SignalChem Lifesciences Corporation |
Aminopyridine derivatives as tam family kinase inhibitors
|
SI3077397T1
(sl)
|
2013-12-06 |
2020-02-28 |
Vertex Pharmaceuticals Inc. |
2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
|
WO2015148654A1
(en)
*
|
2014-03-26 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for inhibiting bmp
|
ES2667424T3
(es)
|
2014-04-24 |
2018-05-10 |
Novartis Ag |
Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa
|
CA2945069A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
US10004732B2
(en)
|
2014-04-24 |
2018-06-26 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
US9670215B2
(en)
|
2014-06-05 |
2017-06-06 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
US11179394B2
(en)
|
2014-06-17 |
2021-11-23 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of Chk1 and ATR inhibitors
|
TWI690525B
(zh)
|
2014-07-07 |
2020-04-11 |
日商第一三共股份有限公司 |
具有四氫吡喃基甲基之吡啶酮衍生物及其用途
|
WO2016011019A1
(en)
|
2014-07-15 |
2016-01-21 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for inhibiting bmp
|
US9359336B2
(en)
|
2014-10-09 |
2016-06-07 |
Allergan, Inc. |
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
ES2691246T3
(es)
*
|
2014-12-02 |
2018-11-26 |
Bayer Cropscience Ag |
Compuestos bicíclicos como pesticidas
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Axlに対するヒトモノクローナル抗体
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
ES2751669T3
(es)
|
2015-02-20 |
2020-04-01 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores FGFR
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016183071A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Hetero-tricyclic compounds and their use for the treatment of cancer
|
RU2729630C2
(ru)
|
2015-06-25 |
2020-08-11 |
Тайхо Фармасьютикал Ко., Лтд. |
Терапевтическое средство для фиброза
|
US9708333B2
(en)
|
2015-08-12 |
2017-07-18 |
Incyte Corporation |
Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
|
US10053465B2
(en)
|
2015-08-26 |
2018-08-21 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as TAM inhibitors
|
WO2017059357A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
EP3365340B1
(en)
|
2015-10-19 |
2022-08-10 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
HUE060680T2
(hu)
*
|
2015-11-19 |
2023-04-28 |
Incyte Corp |
Heterociklusos vegyületek mint immunmodulátorok
|
SG10202005790VA
(en)
|
2015-12-22 |
2020-07-29 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
EP3421039B1
(en)
|
2016-02-26 |
2021-10-06 |
ONO Pharmaceutical Co., Ltd. |
Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
|
HRP20231614T1
(hr)
|
2016-03-28 |
2024-03-15 |
Incyte Corporation |
Spojevi pirolotriazina kao tam inhibitori
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
TW201808902A
(zh)
|
2016-05-26 |
2018-03-16 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
CN109890819B
(zh)
|
2016-06-20 |
2022-11-22 |
因赛特公司 |
作为免疫调节剂的杂环化合物
|
MA45669A
(fr)
|
2016-07-14 |
2019-05-22 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
ES2941716T3
(es)
|
2016-08-29 |
2023-05-25 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
KR102279347B1
(ko)
*
|
2016-12-15 |
2021-07-21 |
한국생명공학연구원 |
피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
|
WO2018111049A1
(ko)
*
|
2016-12-15 |
2018-06-21 |
한국생명공학연구원 |
피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
|
KR102696516B1
(ko)
|
2016-12-22 |
2024-08-22 |
인사이트 코포레이션 |
면역조절제로서의 벤조옥사졸 유도체
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
MA47516A
(fr)
|
2017-02-15 |
2021-03-31 |
Taiho Pharmaceutical Co Ltd |
Composition pharmaceutique
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
EP3673907A4
(en)
|
2017-08-23 |
2020-08-19 |
ONO Pharmaceutical Co., Ltd. |
CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
|
EP3988552A1
(en)
|
2017-09-27 |
2022-04-27 |
Incyte Corporation |
Salts of pyrrolotriazine derivatives useful as tam inhibitors
|
US11826363B2
(en)
|
2017-10-13 |
2023-11-28 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
|
MX2020010321A
(es)
|
2018-03-30 |
2021-01-08 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores.
|
JP2021523121A
(ja)
|
2018-05-04 |
2021-09-02 |
インサイト・コーポレイションIncyte Corporation |
Fgfr阻害剤の固体形態及びその調製プロセス
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
JP7328995B2
(ja)
|
2018-05-11 |
2023-08-17 |
インサイト・コーポレイション |
Pd-l1免疫調節剤としてのテトラヒドロ-イミダゾ[4,5-c]ピリジン誘導体
|
PE20211805A1
(es)
|
2018-06-29 |
2021-09-14 |
Incyte Corp |
Formulaciones de un inhibidor de axl/mer
|
WO2020065453A1
(en)
|
2018-09-29 |
2020-04-02 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
KR102200032B1
(ko)
*
|
2019-03-13 |
2021-01-08 |
전남대학교산학협력단 |
호흡기 질환의 예방 또는 치료용 조성물
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
WO2021030162A1
(en)
|
2019-08-09 |
2021-02-18 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
US11401279B2
(en)
|
2019-09-30 |
2022-08-02 |
Incyte Corporation |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
BR112022007163A2
(pt)
|
2019-10-14 |
2022-08-23 |
Incyte Corp |
Heterociclos bicíclicos como inibidores de fgfr
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
PH12022551136A1
(en)
|
2019-11-11 |
2023-10-09 |
Incyte Corp |
Salts and crystalline forms of a pd-1/pd-l1 inhibitor
|
JP2023505257A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤の誘導体
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
AU2021230385A1
(en)
|
2020-03-06 |
2022-09-22 |
Incyte Corporation |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
US11760756B2
(en)
|
2020-11-06 |
2023-09-19 |
Incyte Corporation |
Crystalline form of a PD-1/PD-L1 inhibitor
|
MX2023005362A
(es)
|
2020-11-06 |
2023-06-22 |
Incyte Corp |
Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
CN115960121A
(zh)
*
|
2022-10-27 |
2023-04-14 |
南通药明康德医药科技有限公司 |
一种合成1-(3-氧杂丁环烷基)-1h-吡唑-4-硼酸频哪醇酯的方法
|